OrbiMed’s Array Biopharma Inc ARRY Stock Holding History

OrbiMed’s Portfolio ARRY Stock Details ARRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-500,000	Closed	-$3.6M	–	145
2015 Q2	$3.6M	Sell	500,000 -600,000	-55%	-$4.43M	0.03%	122
2015 Q1	$8.11M	Buy	+1,100,000	New	+$7.83M	0.07%	108

Other funds holding ARRY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

OrbiMed's ARRY Position: Q4 2018 in Review

OrbiMed sold out of Array Biopharma Inc (ARRY) in Q4 2018, closing a stake of 4,806,900 shares — an estimated $73.1M sold.

OrbiMed first reported a position in ARRY in Q2 2013 and held it in 22 quarters. The position peaked at $174M in Q3 2017. 236 funds tracked by Wall St. Rank hold ARRY as of Q4 2018.

OrbiMed reported no remaining Array Biopharma Inc position as of Q4 2018 after selling out during the quarter.
OrbiMed sold 4,806,900 Array Biopharma Inc shares in Q4 2018, an estimated $73.1M.
OrbiMed first reported a position in Array Biopharma Inc in Q2 2013 and held it in 22 quarters.
OrbiMed's Array Biopharma Inc position peaked at $174M in Q3 2017.
236 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q4 2018.

Based on OrbiMed's 13F filing for Q4 2018, filed 14 Feb 2019.